Cargando…
Immunogenicity in Clinical Practice and Drug Development: When is it Significant?
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070797/ https://www.ncbi.nlm.nih.gov/pubmed/31762152 http://dx.doi.org/10.1111/cts.12717 |
| _version_ | 1783506057579986944 |
|---|---|
| author | Shakhnovich, Valentina Meibohm, Bernd Rosenberg, Amy Kierzek, Andrzej M. Hasenkamp, Rachel Funk, Ryan S. Thalhauser, Craig J. van der Graaf, Piet H. Wang, Yow‐Ming C. Hamuro, Lora |
| author_facet | Shakhnovich, Valentina Meibohm, Bernd Rosenberg, Amy Kierzek, Andrzej M. Hasenkamp, Rachel Funk, Ryan S. Thalhauser, Craig J. van der Graaf, Piet H. Wang, Yow‐Ming C. Hamuro, Lora |
| author_sort | Shakhnovich, Valentina |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7070797 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70707972020-03-17 Immunogenicity in Clinical Practice and Drug Development: When is it Significant? Shakhnovich, Valentina Meibohm, Bernd Rosenberg, Amy Kierzek, Andrzej M. Hasenkamp, Rachel Funk, Ryan S. Thalhauser, Craig J. van der Graaf, Piet H. Wang, Yow‐Ming C. Hamuro, Lora Clin Transl Sci Perspectives John Wiley and Sons Inc. 2019-11-25 2020-03 /pmc/articles/PMC7070797/ /pubmed/31762152 http://dx.doi.org/10.1111/cts.12717 Text en © 2019 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Perspectives Shakhnovich, Valentina Meibohm, Bernd Rosenberg, Amy Kierzek, Andrzej M. Hasenkamp, Rachel Funk, Ryan S. Thalhauser, Craig J. van der Graaf, Piet H. Wang, Yow‐Ming C. Hamuro, Lora Immunogenicity in Clinical Practice and Drug Development: When is it Significant? |
| title | Immunogenicity in Clinical Practice and Drug Development: When is it Significant? |
| title_full | Immunogenicity in Clinical Practice and Drug Development: When is it Significant? |
| title_fullStr | Immunogenicity in Clinical Practice and Drug Development: When is it Significant? |
| title_full_unstemmed | Immunogenicity in Clinical Practice and Drug Development: When is it Significant? |
| title_short | Immunogenicity in Clinical Practice and Drug Development: When is it Significant? |
| title_sort | immunogenicity in clinical practice and drug development: when is it significant? |
| topic | Perspectives |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7070797/ https://www.ncbi.nlm.nih.gov/pubmed/31762152 http://dx.doi.org/10.1111/cts.12717 |
| work_keys_str_mv | AT shakhnovichvalentina immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT meibohmbernd immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT rosenbergamy immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT kierzekandrzejm immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT hasenkamprachel immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT funkryans immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT thalhausercraigj immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT vandergraafpieth immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT wangyowmingc immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant AT hamurolora immunogenicityinclinicalpracticeanddrugdevelopmentwhenisitsignificant |